# Genelux Corporation (GNLX) insider trading

> In the 12 months to Nov 6, 2026, 6 GNLX insiders reported open-market sales of $445.3K across 26 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/gnlx/insider-trading
Latest filing: 2026-11-05 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $445.3K | 26 filings · 6 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 3 of 26 | $108.8K of $445.3K sold (24%) |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Thomas Zindrick | President and CEO | $190.4K | — | 6 | — | 2026-11-05 |
| John Thomas | Director | $108.8K | — | 3 | 100% of sales | 2026-06-02 |
| Yong Yu | SVP, Clinical Development → Chief Scientific Officer | $49.9K | — | 6 | — | 2026-11-05 |
| Joseph Cappello | Chief Technical Officer | $49.8K | — | 6 | — | 2026-11-05 |
| John W. Smither | Director | $34.9K | — | 1 | — | 2026-07-02 |
| Ralph Smalling | Head of Regulatory | $11.5K | — | 4 | — | 2026-06-04 |

## Open-market trades by filing

26 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-05 | 2026-11-03 | Yong Yu | Chief Scientific Officer | Sale | 668 | $2.01 | $1.3K | 258,020 | — |
| 2026-11-05 | 2026-11-03 | Thomas Zindrick | President and CEO | Sale | 3,089 | $2.05 | $6.3K | 1,223,338 | — |
| 2026-11-05 | 2026-11-03 | Joseph Cappello | Chief Technical Officer | Sale | 668 | $2.04 | $1.4K | 317,812 | — |
| 2026-09-02 | 2026-08-31 | Yong Yu | Chief Scientific Officer | Sale | 9,683 | $2.75 | $26.7K | 258,688 | — |
| 2026-09-02 | 2026-08-31 | Thomas Zindrick | President and CEO | Sale | 34,463 | $2.67 | $91.9K | 1,226,427 | — |
| 2026-09-02 | 2026-08-31 | Joseph Cappello | Chief Technical Officer | Sale | 10,257 | $2.74 | $28.1K | 318,480 | — |
| 2026-08-04 | 2026-08-04 | Thomas Zindrick | President and CEO | Sale | 3,023 | $2.95 | $8.9K | 1,260,890 | — |
| 2026-08-04 | 2026-08-04 | Joseph Cappello | Chief Technical Officer | Sale | 653 | $2.95 | $1.9K | 328,737 | — |
| 2026-08-04 | 2026-08-04 | Yong Yu | Chief Scientific Officer | Sale | 653 | $2.94 | $1.9K | 268,371 | — |
| 2026-07-02 | 2026-07-01 | John W. Smither | Director | Sale | 12,000 | $2.91 | $34.9K | 91,403 | — |
| 2026-06-04 | 2026-06-03 | Ralph Smalling | Head of Regulatory | Sale | 192 | $2.93 | $563 | 67,611 | — |
| 2026-06-02 | 2026-06-01 | John Thomas | Director | Sale (10b5-1) | 10,000 | $2.98 | $29.8K | 472,784 | — |
| 2026-05-12 | 2026-05-11 | Ralph Smalling | Head of Regulatory | Sale | 270 | $2.98 | $804 | 67,803 | — |
| 2026-05-12 | 2026-05-11 | Thomas Zindrick | President and CEO | Sale | 2,798 | $2.94 | $8.2K | 532,051 | — |
| 2026-05-12 | 2026-05-11 | Yong Yu | Chief Scientific Officer | Sale | 605 | $2.97 | $1.8K | 149,706 | — |
| 2026-05-12 | 2026-05-11 | Joseph Cappello | Chief Technical Officer | Sale | 605 | $2.97 | $1.8K | 154,549 | — |
| 2026-03-26 | 2026-03-24 | Thomas Zindrick | President and CEO | Sale | 3,582 | $2.42 | $8.7K | 534,849 | — |
| 2026-03-26 | 2026-03-24 | Yong Yu | SVP, Clinical Development | Sale | 906 | $2.42 | $2.2K | 144,938 | — |
| 2026-03-26 | 2026-03-24 | Joseph Cappello | Chief Technical Officer | Sale | 906 | $2.42 | $2.2K | 155,154 | — |
| 2026-03-26 | 2026-03-24 | Ralph Smalling | Head of Regulatory | Sale | 585 | $2.46 | $1.4K | 68,073 | — |
| 2026-03-03 | 2026-03-02 | John Thomas | Director | Sale (10b5-1) | 10,000 | $2.90 | $29.0K | 482,784 | — |
| 2025-12-11 | 2025-08-21 | Joseph Cappello | Chief Technical Officer | Sale | 3,706 | $3.88 | $14.4K | 156,060 | — |
| 2025-12-11 | 2025-08-21 | Yong Yu | SVP, Clinical Development | Sale | 4,192 | $3.82 | $16.0K | 145,844 | — |
| 2025-12-11 | 2025-08-21 | Thomas Zindrick | President and CEO | Sale | 17,182 | $3.86 | $66.4K | 538,431 | — |
| 2025-12-09 | 2025-08-21 | Ralph Smalling | Head of Regulatory | Sale | 2,332 | $3.75 | $8.7K | 68,658 | — |
| 2025-12-02 | 2025-12-01 | John Thomas | Director | Sale (10b5-1) | 10,000 | $5.00 | $50.0K | 492,784 | — |

## Other insider activity (not market trades)

- Grants and awards: 9 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Role**: The title on each filing. Someone whose title changed shows more than one.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has the Genelux Corporation's CEO sold stock?

Yes. Thomas Zindrick (CEO) sold 64,137 shares ($190.4K) between Dec 2025 and Nov 2026.

### How current is GNLX’s insider data?

These are GNLX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The GNLX Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=GNLX&filing_date.gte=2025-11-06&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Genelux Corporation (GNLX) stock price](https://massive.com/quote/gnlx.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms